Európska únia - slovinčina - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazol - schizophrenia; bipolar disorder - psiholeptiki - zdravilo abilify je indicirano za zdravljenje shizofrenije pri odraslih in pri mladostnikih, starih 15 let ali več. abilify je primerna za zdravljenje zmerno do hudo manične epizode v bipolarne motnje i bolezni in za preprečevanje novo manično epizodo pri odraslih, ki so imeli pretežno manične epizode in katerih manične epizode se odzvali na zdravljenje aripiprazole. abilify je primerna za zdravljenje do 12 tednov, z zmerno do hudo manične epizode v bipolarne motnje i motnje pri mladostnikih, ki so stari 13 let in starejši.

Európska únia - slovinčina - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenem natrij - bakterijske okužbe - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 in 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Európska únia - slovinčina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - levetiracetam - epilepsija - drugi antiepileptics - zdravilo levetiracetam sun je indicirano kot monoterapija pri zdravljenju napadov s parcialnim nastopom s sekundarno generalizacijo ali brez nje pri bolnikih od 16. leta starosti z novo diagnosticirano epilepsijo. levetiracetam sonce je označen kot adjunctive terapija:pri zdravljenju delno-nastop napadi z ali brez sekundarne posplošitev v odrasle in otroke od štirih let z epilepsijo;pri zdravljenju myoclonic zasegov v odrasle in mladostnike od 12. leta starosti z mladoletnimi myoclonic epilepsija;v zdravljenju primarne splošni tonik-clonic zasegov v odrasle in mladostnike od 12. leta starosti z idiopatsko splošnih epilepsijo. levetiracetam sonce koncentrat je alternativa za bolnike, ko ustni uprava je začasno ni izvedljivo,.

Európska únia - slovinčina - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Európska únia - slovinčina - EMA (European Medicines Agency)

bracco international b.v. - žveplov heksafluorid - ultrasonography; echocardiography - kontrastni mediji - to zdravilo je samo za diagnostično uporabo. sonovue je za uporabo z ultrazvočno slikanje za izboljšanje echogenicity krvi ali tekočine v sečil, ki ima za posledico izboljšano signalom in šumi. sonovue lahko uporablja samo pri bolnikih, kjer študija brez kontrast opreme je nejasni. echocardiographysonovue je transpulmonary echocardiographic kontrastno sredstvo za uporabo pri odraslih bolnikih z domnevno ali sedež bolezni srca in ožilja zagotoviti opacification srčne komore in povečanje levega prekata endocardial meji razmejitve. doppler macrovasculaturesonovue poveča natančnost v odkrivanje ali trajna izključitev ali nepravilnosti v cerebralne arterije in extracranial karotidne ali perifernih arterij pri odraslih bolnikih z izboljšanjem doppler signalom in šumi. sonovue poveča kakovost doppler pretok slike in trajanje klinično uporabni signal opremo v portal veno oceno pri odraslih bolnikih,. doppler microvasculaturesonovue izboljša prikaz vaskularnost jeter in prsi poškodb med doppler sonography pri odraslih bolnikih, ki vodijo do bolj specifičnih lezije opredelitev. ultrazvok je od excretory sečil tractsonovue je primerna za uporabo v ultrazvok v excretory trakta v pediatričnih bolnikih od novorojenčka do 18 let za odkrivanje vesicoureteral refluks. za omejitev pri razlagi negativno urosonography.

Európska únia - slovinčina - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - brexpiprazole - shizofrenija - psiholeptiki - zdravljenje shizofrenije.

Európska únia - slovinčina - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazol - shizofrenija - psiholeptiki - vzdrževalno zdravljenje shizofrenije pri odraslih bolnikih, stabiliziranih s peroralnim aripiprazolom.

Európska únia - slovinčina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Európska únia - slovinčina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Slovinsko - slovinčina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

jubilant pharmaceuticals - escitalopram - filmsko obložena tableta - escitalopram 15 mg / 1 tableta - escitalopram